NatWest Group is taking a minority stake in London-based fintech Bourn, according to a report […] The post NatWest Group Takes Minority Stake in Bourn to Boost SME Working Capital Innovation appeared first on FF News | Fintech Finance.NatWest Group is taking a minority stake in London-based fintech Bourn, according to a report […] The post NatWest Group Takes Minority Stake in Bourn to Boost SME Working Capital Innovation appeared first on FF News | Fintech Finance.

NatWest Group Takes Minority Stake in Bourn to Boost SME Working Capital Innovation

2025/12/02 00:45
Okuma süresi: 2 dk

NatWest Group is taking a minority stake in London-based fintech Bourn, according to a report by Sky News, as the high street bank looks to boost innovation in how it serves business customers.

Bourn, launched last year to help small and medium-sized enterprises tackle persistent cashflow pressures, is raising £3.5m in a new funding round in which NatWest is participating. Other backers in the round include Portfolio Ventures, McPike Global Family Office, Haatch, Love Ventures and Aperture, with the fresh capital earmarked to speed up the rollout of Bourn’s flagship product, the Flexible Trade Account (FTA).

The FTA is billed by Bourn as a modern take on the traditional business overdraft, embedding overdraft-style flexibility directly into the existing bank accounts and financial platforms used by SMEs, and aiming to strip out friction so capital can move more quickly to where it’s needed.

“2025 has been a year of validation, proving that SMEs and their funding partners need a more modern, data-driven approach to working capital,” Nick Tracey, Bourn’s co-founder and chief executive, said. “This investment round shows that established banks see the same opportunity we do: to bring liquidity closer to the point of need and help businesses fund growth more dynamically. Our goal is to reinvent the business overdraft for SMEs. When working capital flows easily, businesses invest, hire and grow. That’s how we make finance work for the real economy again.”

For NatWest, led by chief executive Paul Thwaite, the deal is intended to pave the way for collaboration between the bank and Bourn to support mid-market and wider business customers. NatWest plans to use insights from the FTA to explore how embedded working capital tools can bolster cashflow access for entrepreneurs and established firms alike.

“Now more than ever, SMEs need the right support to scale and grow – which is why Bourn’s offering has so much potential,” said Ladi Greenstreet, head of strategic investments at NatWest. “Their founding team combines deep banking expertise with genuine fintech innovation, while their capabilities complement our ambition to help customers access working capital seamlessly through the platforms they already use. Supporting Bourn reinforces our commitment to helping fintechs thrive while ensuring our commercial mid-market customers can access the funding and support they need.”

The post NatWest Group Takes Minority Stake in Bourn to Boost SME Working Capital Innovation appeared first on FF News | Fintech Finance.

Piyasa Fırsatı
Boost Logosu
Boost Fiyatı(BOOST)
$0.000167
$0.000167$0.000167
-8.64%
USD
Boost (BOOST) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen service@support.mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Paylaş
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Paylaş
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Paylaş
BitcoinEthereumNews2025/09/18 05:26